Naloxone

• Opioid overdose emergency reversal
• Reversal of opioid-induced respiratory depression
• Post-operative opioid reversal
• Community overdose prevention programs
• Harm reduction interventions

Naloxone is a pure opioid receptor antagonist that rapidly reverses the life-threatening effects of opioid overdose, particularly respiratory depression. Marketed under brand names including Narcan and Kloxxado, it is available as a nasal spray, intramuscular injection, and auto-injector, and is now sold over the counter in most states without a prescription. Naloxone has become a centerpiece of public health response to the opioid crisis: it is carried by first responders, distributed through community harm-reduction programs, and increasingly kept in workplaces, schools, and homes where opioid exposure is possible. Anyone who uses prescription opioids, anyone with a household member who uses opioids, and anyone in a position to witness an overdose should have naloxone on hand and know how to use it.

Mechanism of Action

Naloxone is a competitive antagonist at all three classical opioid receptor types — mu, kappa, and delta — with highest affinity for the mu receptor that mediates most opioid-induced respiratory depression, sedation, and analgesia. When administered to a person experiencing opioid toxicity, naloxone displaces opioid molecules from the receptor and blocks further binding, rapidly restoring the brainstem's drive to breathe. Because naloxone has no intrinsic agonist activity, it produces no opioid effects of its own; in an opioid-naive person, it is essentially inert.

After intranasal administration, plasma concentrations rise within 8 to 13 minutes, with clinical effect typically apparent in 2 to 5 minutes. Intramuscular administration produces peak plasma levels at about 15 minutes but onset of action is similar. Intravenous naloxone, used in hospital settings, works within 1 to 2 minutes. The half-life of naloxone is short — roughly 30 to 90 minutes — and importantly, the half-life of most opioids that cause overdose is longer. This means the antagonist effect can wear off before the offending opioid has cleared, allowing renarcotization. This is especially true for long-acting agents such as methadone, extended-release oxycodone, fentanyl analogues, and high-dose morphine. Repeat dosing is therefore frequently necessary, and continued monitoring after initial reversal is essential.

Clinical Use

Naloxone is indicated for the emergency treatment of known or suspected opioid overdose, including overdose from prescription opioids, illicit opioids such as heroin, and synthetic opioids such as fentanyl. It is also used in operating rooms and recovery units to reverse opioid effects after surgery and to manage opioid-induced respiratory depression in palliative care, though smaller, titrated doses are used in those settings to avoid abrupt loss of analgesia. The Centers for Disease Control and Prevention and the American Society of Addiction Medicine strongly recommend co-prescribing naloxone with opioid prescriptions for patients on doses of 50 morphine milligram equivalents per day or higher, those on concurrent benzodiazepines, those with substance use disorders, and those with respiratory conditions.

In community use, naloxone is the cornerstone of overdose prevention. Suspect opioid overdose when someone is unresponsive, breathing slowly or not at all, has pinpoint pupils, and has gray, blue, or pale skin and lips. Indicators such as nearby drug paraphernalia or an empty pill bottle increase suspicion. Naloxone should be given immediately while emergency services are summoned. Alternative antagonist therapy includes naltrexone, an oral and injectable mu-antagonist used for maintenance treatment of opioid use disorder, but naltrexone is not appropriate for acute overdose reversal because of slower onset and longer duration. The CDC overdose prevention resources at cdc.gov and SAMHSA materials at samhsa.gov provide patient and family training guidance.

How to Take It

Naloxone nasal spray is the most widely available formulation. To administer, lay the person on their back, peel open the device package, hold the device with thumb on the plunger and two fingers on the nozzle, insert the nozzle into one nostril until fingers touch the bottom of the nose, and press the plunger firmly. The full dose is delivered in a single spray. Call 911 immediately — naloxone is a bridge to definitive medical care, not a substitute for it. Begin or continue rescue breathing if the person is not breathing. If there is no response within 2 to 3 minutes, give a second dose in the other nostril; additional doses may be needed for high-potency opioid overdoses such as fentanyl.

The intramuscular auto-injector talks the user through the steps and delivers the dose into the outer thigh, through clothing if necessary. After administration, place the person in the recovery position (lying on the side with the upper leg bent forward) to protect the airway in case of vomiting. Stay with the person until emergency responders arrive, even if they appear to recover, because renarcotization is common. Naloxone should be stored at room temperature, away from light and freezing, and replaced at expiration. Devices should not be primed or test-sprayed before use — each unit contains a single dose. The MedlinePlus naloxone monograph at medlineplus.gov provides clear patient-facing instructions.

Monitoring and Follow-Up

After naloxone administration, the recipient must be observed continuously until either professional emergency responders take over or the person remains alert and breathing normally for at least 2 hours after the last dose, since renarcotization can occur as naloxone clears the system. Vital signs — particularly respiratory rate and oxygen saturation — should be monitored. Mental status, pupil size, and skin color provide useful real-time assessment.

After the acute event, every overdose survivor should be evaluated for opioid use disorder and connected with treatment resources. Hospital observation is standard for most overdose presentations, with longer monitoring after long-acting opioid exposure. The American Society of Addiction Medicine recommends initiation of medication for opioid use disorder — buprenorphine, buprenorphine-naloxone, or methadone — during the post-overdose hospitalization when possible. Naloxone refill should be provided at discharge along with overdose prevention training for family and friends. Patients with chronic pain who experienced overdose should have their opioid regimen reassessed, with consideration of dose reduction, rotation to safer agents, or transition to non-opioid strategies such as multimodal pain management.

Special Populations

Naloxone is safe across all age groups, including infants and children — pediatric opioid exposures, accidental ingestions, and neonatal opioid withdrawal syndrome can all be addressed with weight-appropriate dosing. The standard adult intranasal device is appropriate for children of any size in suspected overdose. In pregnancy, naloxone given to a mother experiencing overdose can precipitate withdrawal that may stress the fetus, but maternal survival takes precedence — the medication is given when needed without hesitation. Postpartum women with a history of opioid use disorder should leave the hospital with naloxone.

Elderly patients tolerate naloxone well; the drug has no organ-toxic effects in healthy populations. No dose adjustment is required for renal or hepatic impairment. Patients with cardiovascular disease should be observed carefully after reversal because abrupt withdrawal can drive elevations in blood pressure, heart rate, and catecholamine release that may stress a vulnerable heart. Patients with chronic pain on prescription opioids should be educated that naloxone in their possession is for emergency rescue use by family or bystanders, not for self-administration.

When to Contact Your Doctor

Always call 911 when administering naloxone — this is non-negotiable. Even if the person wakes up and seems to recover, emergency department evaluation is essential because the opioid effect may return as naloxone wears off. Persistent unresponsiveness despite multiple naloxone doses may indicate non-opioid causes of altered consciousness such as hypoglycemia, head injury, stroke, or co-ingestion of sedatives such as benzodiazepines or alcohol that naloxone cannot reverse. New chest pain, difficulty breathing, severe agitation, seizures, vomiting with concern for aspiration, or any cardiovascular instability after naloxone administration warrants emergency evaluation. Acute opioid withdrawal symptoms — sweating, tachycardia, vomiting, diarrhea, body aches — are uncomfortable but not immediately life-threatening; medical care can provide supportive treatment.

If you or a family member uses opioids, want to obtain naloxone, or need education on overdose prevention, contact us or schedule a visit with the Zimmer Medical Group team to ensure you are prepared.